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OncoAge, Nice, France
2CNRS, INSERM, Institute of Research on Cancer and Ageing of Nice (IRCAN), Universite Côte d’Azur, University Hospital Federation
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Abstract
Background Recent advances obtained with immune checkpoint inhibitors (ICIs) targeting the programmed cell
death-1 (PD-1) protein have significantly improved the outcome of patients with metastatic melanoma. The PD-L1
expression in tumour cells as detected by immunohistochemistry is a predictive biomarker in some solid tumours, but
appears insufficient as prognostic or predictive factor of response to ICIs in metastatic melanomas.
Objectives We investigated whether the presence and the features of pretreatment CD8+tumour-infiltrating T lympho-
cytes (TILs) could be a complementary prognostic or predictive biomarker in patients with metastatic melanoma.
Methods In this retrospective study, we evaluated the association of PD-L1 expression ≥5% of tumour cells combined
with TIL features (CD8, CD28, Ki67) with the overall survival (OS) among 51 patients treated with ICIs and 54 patients
treated with other treatment options (non-ICIs).
Results PD-L1 positivity was observed in 33% and 39% of primary melanomas and matched metastases, respectively, with,
however, poor concordance between the primary and the matched metastatic site (j = 0.283). No significant association was
noted between PD-L1 expression and CD8+TIL profile analysed as single markers and OS or response to immunotherapy.
Instead, their combined analysis in primary melanoma samples showed that the PD-L1/CD8+status was significantly associ-
ated with prolonged OS in the whole population (P = 0.04) and in the subgroup treated with non-ICIs (P = 0.009). Conversely,
the PD-L1+/CD8+ status was a good prognostic factor in patients treated with ICIs (P = 0.022), whereas was significantly asso-
ciated with poor prognosis in patients treated with non-ICIs (P = 0.014). While the expression of CD28 was not related to out-
come, the Ki67 expression was significantly associated with poor OS in the subgroup CD8+TIL+/PD-L1 (P = 0.02).
Conclusions The pretreatment combination of PD-L1 expression with the level of CD8+TILs could better assess OS
and predict therapeutic response of patients with metastatic melanoma treated by either immunotherapy or other treat-
ment regimens.
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Introduction
Malignant melanoma is among the types of cancer whose inci-
dence and mortality significantly increased in the last decades. A
total of 232 000 new cases are diagnosed, and more than 55 000
patients die from a metastatic melanoma each year across the
world.1 Metastatic melanoma represents a highly aggressive form
of skin cancer, with an overall 5-year survival rate of <20% and a
median survival time of approximately 9 months for stage IV dis-
ease.2
The advent of the immunotherapy strategies, in particular the
immune checkpoint inhibitors (ICIs) targeting programmed
death-1 (PD-1) and its ligand PD-L1, represented a true paradigm
shift with an impressive 58% increase in the 3-year median sur-
vival.3–5 Following the first phase I study evaluating nivolumab,5
several clinical trials have investigated the use of immunohisto-
chemically (IHC) expression of PD-L1 in tumour cells as a bio-
marker to predict response to anti-PD-1/PD-L1 ICIs. PD-L1
expression in tumour cells was found to predict a good response
to immunotherapy; however, a significant clinical benefit was also
observed in patients whose tumour did not express PD-L1.6,7 Dur-
able response to ICIs is limited to a subset of melanoma patients,
while 40% of patients do not respond to anti-PD-1 inhibitors in
monotherapy. In most clinical trials, the expression of PD-L1 IHC
alone did not allow optimal selection of responding patients.4 This
biomarker currently appears insufficient to predict a therapeutic
response to ICIs in patients with metastatic melanoma, paving the
way for further research to optimize predictive tests.
Moreover, the prognostic value of the PD-L1 expression in
patients with metastatic melanoma remains controversial,
reportedly being associated with either poor or good prognosis
according to various studies.8–11 Therefore, PD-L1 expression
does not appear to be a reliable prognostic biomarker for routine
practice.
While PD-L1 alone is currently inadequate, as prognostic
and predictive marker in metastatic melanoma, other potential
biomarkers are currently emerging. The presence of intratu-
mour CD8+ tumour-infiltrating lymphocytes (CD8+TIL) could
prove to be an important prognostic and predictive marker,
particularly in association with the expression of PD-L1 in
tumour cells.11 Some studies have shown the importance of
the microenvironment including the analysis of CD8+TIL and
the potential correlation with a good response to anti-PD-1
inhibitors in some solid tumours, including metastatic
melanoma.7,11–13
The classification of tumours into four groups, based on the
presence or absence of CD8+TILs and the expression of PD-L1
in tumour cells, has recently been proposed to predict the
response to immunotherapy.14 However, studies evaluating the
impact of such classification for the stratification of melanoma
patients treated with immunotherapy are limited.15,16
Recent studies demonstrated that PD-1 suppresses T-cell
function primarily by inactivating CD28 signalling, while the
rescue of exhausted CD8+ TILs by PD-1 targeted therapies is
CD28-dependent, suggesting that T-cell costimulatory receptor
CD28 could be a primary target for PD-1-mediated inhibi-
tion.17,18
The objective of our study was to correlate the expression of
PD-L1 in tumour cells, combined with the quantification of
CD8+TILs and their activation status (CD28, Ki67), to overall
survival (OS) and response to treatment in order to determine
whether this combination could be a more effective prognostic
and predictive biomarker than IHC PD-L1 alone.
Patients and methods
Study population
This retrospective cohort included patients with primary cuta-
neous metastatic malignant melanoma (stage III/IV) diagnosed
between July 2013 and February 2017 and treated at the Depart-
ment of Dermatology, University of Nice, Archet 2 Hospital
(Nice, France). The formalin-fixed paraffin-embedded (FFPE)
tumour samples were retrieved from different laboratories: Lab-
oratory of Clinical and Experimental Pathology (Pasteur Hospi-
tal, Nice, France), Medipath (Mougins, France), DIAG (Nice,
France) and CAP (Nice, France). The availability of histological
material from the primary tumour and metastasis was a required
criterion to include a case in the study.
A total of 202 patients with metastatic melanoma were ini-
tially included in the study. Out of these, 97 (48%) were
excluded for various reasons (primary melanoma not available,
small size of the sample, regressed primary melanoma, mucosal
melanoma) leaving 105 patients in which the primary tumour
and the first metastasis were available. Out of 105 patients, 91
presented with regional metastases (35 in transit and 56 lymph
node metastases) and 14 with distant metastases (eight lung, and
six subcutaneous).
The LDH levels at baseline were measured before initiation of
the systemic treatment. The assay was performed in 76 patients.
Two groups of patients were distinguished for this study: a
group of 51 patients (48.5%) who received at least one treatment
of immunotherapy (anti-PD-1 inhibitors – pembrolizumab/
nivolumab and/or anti-CTLA4) and a group of 54 patients
(51.5%) who have not had immunotherapy treatment, albeit
some had other treatments (chemotherapy or targeted therapies
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with anti-BRAF and anti-MEK agents). Among the 51 patients
of the group treated with immunotherapy, 29 (57%) have had
exclusively immunotherapy while 22 (43%) have received an
immunotherapy treatment before or after having other treat-
ments (chemotherapy or targeted therapies).
All tumour specimens were used with the informed consent
from the patients (Hospital-Integrated Biobank BB-0033-00025,
Pasteur Hospital, Nice, France).
Histology analysis
Specimens were fixed in 10% formalin, embedded in paraffin
and 4-lm-thick serial tissue sections obtained and stained with
haematoxylin and eosin (H&E) for histologic evaluation. The
H&E-stained sections were independently assessed by two
pathologists (CBE and VH), and the histopathological data
including histologic subtype, Breslow thickness, ulceration and
TNM stage were recorded. The primary malignant melanomas
were reclassified with the 8th edition of the AJCC (American
Joint Committee Cancer) tumour, node and metastasis classifi-
cation. The density of the inflammatory infiltrate (none, mild,
moderate, marked) and its location were assessed to determine
the presence or the absence of TILs.
Immunohistochemical analysis
Formalin-fixed paraffin-embedded freshly cut serial 4-lm-thick
tissue sections, mounted on positively charged slides, were
stained for PD-L1 with the anti-human PD-L1 rabbit mono-
clonal antibody, clone 28-8 (kit PD-L1 PharmDx; Dako, Car-
pinteria, CA, USA). PD-L1 IHC was performed using a
Autostainer Link 48 Dako-automated staining instrument,
according to the manufacturer’s recommendations. Staining
was performed within two steps: a pre-pretreatment phase (PT
Link Dako and EnVision FLEX Target Retrieval low pH solu-
tion) during 53 min and then the tissue sections were incu-
bated with PD-L1 antibody during 30 min with the other
components of the PD-L1 28-8 pharmDx kit, followed with a
wash buffer (EnVision FLEX, Dako) and a 7-min counter-
stained with haematoxylin (EnVision FLEX, Dako).
In addition, CD8, CD28 and Ki67 IHC assays were performed
using a BenchMark ULTRA-automated staining instrument
(Ventana Medical Systems, Tucson, AZ, USA). FFPE freshly cut
serial tissue sections were stained with a rabbit monoclonal anti-
CD8 antibody (clone SP57; Ventana), a rabbit polyclonal anti-
CD28 antibody (SIGMA Life Science, St. Louis, MO, USA) and
a rabbit monoclonal anti-Ki67 antibody (clone 30-9; Ventana).
Each IHC run contained a positive control (tonsil) and a neg-
ative Ab control (buffer, no primary Ab).
Staining evaluation
The IHC staining was independently assessed by two patholo-
gists (CBE and VH). When a discrepancy between the patholo-
gists was noted, the slides were jointly reviewed on a multihead
microscope with a third pathologist (MI or PH) to obtain a con-
sensus.
PD-L1 staining was assessed on tumour cells and was consid-
ered positive if at least 5% of the tumour cells exhibited mem-
branous PD-L1 staining of any intensity in a tissue section
containing at least 100 cells that could be evaluated, as previ-
ously described in clinical trials using the corresponding anti-
PD1/PD-L1 inhibitors.4,19,20
Assessment of CD8+TILs was performed by using Clark’s
modified grading system, as recommended by the International
Immuno-Oncology Biomarkers Working Group.21,22 This grad-
ing system is based on the density (absent/mild/moderate/
marked, based on H&E staining, score 0–3) and distribution
(absent/focal/multifocal/diffuse, score 0–3) of TILs expressing
CD8 at a threshold of 10%.21,22 TILs were defined as lympho-
cytes infiltrating and disrupting tumour nests and/or in direct
contact with tumour cells. The possible combinations were col-
lapsed into four TIL grades as follows: grade 0 = absent; grade
1 = mild or moderate focal infiltrate, or mild multifocal infil-
trate; grade 2 = marked focal, moderate or marked multifocal or
mild diffuse infiltrate; grade 3 = moderate or marked diffuse
infiltrate. Intense infiltrate referred to a strong heavy lympho-
cytic infiltrate of a density equivalent to that seen in a lymph
node with metastasis.23 Intratumoral TILs were defined as lym-
phocytes infiltrating and disrupting tumour nests and/or in
direct contact with the invasive tumour area as observed by
haematoxylin and eosin staining. Peritumoral TILs were defined
as lymphocytes located at distance from the tumour area,
perivascular and inside the stromal fibrosis. The grades 1–3 TILs
expressing CD8 at a threshold of 10% defined the
CD8+TILpositive group.
Primary tumours and the matched metastases were classified
in four groups on the basis of their PD-L1 IHC status and pres-
ence (grade 1–3) or absence of CD8+TILs: (i) CD8+TIL+/PD-
L1+; (ii) CD8+TIL/PD-L1; (iii) CD8+TIL+/PD-L1; and (iv)
CD8+TIL/PD-L1+. In order to better define the activated T
lymphocytes, CD28 and Ki67 were analysed only in the
CD8+TILpositive group (n = 64).
CD28 staining was assessed considering the percentage of
lymphocytes staining for CD28 compared to the lymphocytes
staining for CD8. Similarly, the assessment of Ki67 was per-
formed considering the percentage of lymphocytes stained for
Ki67 compared to the lymphocytes staining for CD8.
BRAFmolecular analysis
The BRAF mutational status was determined on tumour
DNA isolated from FFPE tissue samples of melanoma metas-
tases using the QIAamp DNA FFPE tissue kit (Qiagen, Hil-
den, Germany), according to the manufacturer’s instructions.
Pyrosequencing of BRAF exon 15 using the Therascreen
BRAF Pyro Kit (Qiagen) was performed as previously
described.24
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Statistical analysis
All statistical analyses were performed at alpha risk = 5% under
bilateral assumption using R.3.2.3 software (https://cran.r-projec
t.org/bin/windows/base/old/3.2.3/) on Windows. Qualitative
data were presented as absolute frequencies, percentages, 95%
confidence intervals, missing data percentages. These data were
compared using the chi-square test or the Fisher test in case of
non-compliance with chi-square application conditions. Quanti-
tative data were described by medians, extremes, means, stan-
dard deviations and percentages of missing data. These data
were compared using Student’s t-test or the Mann–Whitney test
in case of non-compliance with the Student test conditions.
Overall survival (OS) since primary was defined as the interval
between the date of diagnosis of the primary tumour and the
date of death of the patient or of the last follow-up. OS since the
first metastasis was defined as the interval between the date of
diagnosis of the first metastasis and the date of death of the
patient or of the last follow-up. Patients lost to follow-up were
censored on the date of last contact. These data were described
by survival rates, survival medians and 95% confidence intervals.
The survival curves were compared by the log-rank test. Kaplan–
Meier survival curves were determined to assess the prognostic
significance of PD-L1 expression and CD8+TILs (grades 1–3) on
OS. The cut-off predicting OS for CD28 expression level and Ki-
67 index was evaluated graphically by using inflection points of
the smoothing spline curve fit for both analytes and confirmed
by using statistical rules assessed using R function ‘bestcut2’ for
survival data model. Thus, the cut-off was defined at 20 for both
analytes. Multivariate analyses were performed using Cox regres-
sion models with corresponding adjusted hazard ratio (HR)
calculations. For the whole study, maximum patient follow-up




The main clinical and histomolecular characteristics of this
cohort are shown in Table 1. The PD-L1 expression ≥5%
tumour cells was observed in 35 out of 105 (33.3%) primary
melanomas (range, 5–50%) and in 41 out of 105 (39%) first
metastasis of the matched primary melanoma (range, 5–100%).
There was a poor intrapatient concordance between PD-L1
expression status of the primary melanoma and the first meta-
static site (j = 0.283; 95% CI, 0.072–0.494).
PD-L1 expression was membranous, essentially heterogeneous
and focal, most often at the periphery of the tumour, located at
the tumour invasion front (Fig. 1). The mononuclear cells of the
tumour microenvironment were mostly lymphocytes with occa-
sional plasma cells or macrophages. This infiltrate was most
often located at the border of the tumour areas, as aggregates,
and/or more rarely intratumoral as isolated cells. The
topography and density of this infiltrate was clearly visible on
the IHC CD8 staining (Fig. 2).
Correlations with the clinicopathological characteristics
There was a significant association between the PD-L1 expres-
sion status (≥5% tumour cells) and the presence of CD8+TILs
(P = 0.008, Table 2).
More than half of primary melanomas were infiltrated with
CD8+TILs (64/105; 60.9%; grades 1–3). The classification into
four subgroups based on the PD-L1 status and the presence or
absence of CD8+TILs (grades 1–3)14 showed that the subgroups
PD-L1/TILs+ (34%) and PD-L1/TILs (32%) were the most
represented, followed by the subgroup PD-L1+/TILs+ (27%),
while the subgroup PD-L1+/TILs (7%) was poorly represented
(Table 2, Fig. 3).
In the metastatic lesions, CD8+TILpositive status was
observed in 46.6% (49/105) of cases and the distribution of
groups showed a predominance of the PD-L1/TIL group (45%)
followed by the PD-L1+/TILs+ group (30%) and a significant
decrease in the PD-L1/TILs+ infiltrates (16%). The PD-L1+/
TILs group was poorly represented (9%; P < 0.001, Table 2).
There was no significant correlation between the CD28 and Ki67
expression in the 64 primary melanomas (P = 0.70). Moreover,
there was no significant association between the PD-L1 status and
gender (P = 0.46), histological subtype (P = 0.23), ulceration
(P = 0.37), AJCC-T subgrouping (P = 0.54) or stage (P = 0.19),
BRAF status (P = 0.39) and LDH level at baseline (P = 0.15).
No significant difference was observed for all of these data in
the two groups of patients receiving or not immunotherapy
treatment, except for age. Patients treated with immunotherapy
were slightly younger than patients not receiving immunother-
apy (median, 60 years vs. 66 years, P = 0.031).
Overall survival analysis in the whole population
The pTNM stage, high baseline LDH levels and the presence of
ulceration were significantly associated with poor OS in our
population (P = 0.044, P = 0.043 and P = 0.00068, respec-
tively). Conversely, independently adjusted PD-L1 expression
and CD8+TIL status were not significantly correlated with OS
(P = 0.50 and P = 0.27, respectively).
The OS analysis according to the CD8+TILs/PD-L1 status
showed that the PD-L1/TILs+ subgroup compared to the
other groups analysed together demonstrated better OS
(P = 0.041, Fig. 4b). The percentage of patients alive at
60 months was 72% (26/36) for the PD-L1/TILs+ subgroup
compared to 50% (35/69) for all patients in the other three
groups combined.
Among the 64 primary melanomas tested, the CD28
expression was not a significant prognostic factor for OS,
independently of the cut-off (20, P = 0.253; and 70,
P = 0.343 respectively; data not shown). Similarly, when the
CD28 expression was adjusted according to the subgroups
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PD-L1+/TILs+ and PD-L1/TILs+, no significant difference
was observed, regardless of the cut-off (P = 0.06, P = 0.936,
P = 0.297, P = 0.319; data not shown).
In contrast, the Ki67 expression analysed alone and in the
PD-L1/CD8+TIL+ subgroup was a significant prognostic factor
for poor OS (P = 0.02; data not shown).
The multivariate analysis, adjusted according to age, histologi-
cal type, presence of ulceration and pTNM stage, showed that
the PD-L1/TILs+ subgroup was a significant independent prog-
nostic factor for better OS (HR, 0.41; 95% CI, 0.17–0.98;
P = 0.04).
Finally, the univariate OS analyses described for the primary
melanomas were also performed according to the expression
levels on the first metastasis, regardless of the metastatic site. The
expression of PD-L1, the status CD8+TIL and CD8+TIL/PD-L1
subgroups were not significantly related to OS (data not shown).
Table 1 Clinical and histomolecular characteristics of the metastatic melanoma cohorts treated by chemotherapy or immunotherapy
Characteristics Immunotherapy-naive
patients (n = 54), %
Patients treated by
immunotherapy
(n = 51), %
Total
(n = 105), %
P-value*
Gender 0.30
Female 21 (60.00) 14 (40.00) 35 (33.33)
Male 33 (47.14) 37 (52.86) 70 (66.67)
Age (years)
Mean 66.59 60.55 63.66 0.031
Range 23–92 26–83 23–92
LDH baseline 0.99
Normal 26 (40.00%) 39 (60.00%) 65




30 (53.57) 26 (46.43) 56 (53.33)
Nodular melanoma 15 (46.88) 17 (53.12) 32 (30.48)
Acral lentiginous
melanoma
3 (50.00) 3 (50.00) 6 (5.71)
Invasive lentigo
maligna melanoma
3 (75.00) 1 (25.00) 4 (3.81)
Not classified 3 (42.85) 4 (57.14) 7 (6.67)
Ulceration 0.77
Absent 25 (49.02) 26 (50.98) 51 (48.57)
Present 29 (53.70) 25 (46.30) 54 (51.43)
pT stage 0.84
T1 7 (58.33) 5 (41.67) 12 (11.43)
T2 10 (55.56) 8 (44.44) 18 (17.14)
T3 20 (52.63) 18 (47.37) 38 (36.19)
T4 17 (45.95) 20 (54.05) 37 (35.24)
pN stage 0.58
N0 47 (52.22) 43 (47.78) 90 (85.71)
N1a 0 (0.00) 1 (100.00) 1 (0.95)
N1b 0 (0.00) 1 (100.00) 1 (0.95)
N1c 6 (60.00) 4 (40.00) 10 (9.52)
N3 1 (33.33) 2 (66.67) 3 (2.86)
Stage at diagnosis 0.53
I 13 (61.90) 8 (38.10) 21 (20.00)
II 34 (50.00) 34 (50.00) 68 (64.76)
III 7 (46.67) 8 (53.33) 15 (14.28)
IV 0 (0.00) 1 (100.00) 1 (0.95)
BRAF status 0.071
Mutation 25 (62.50) 15 (37.50) 40 (38.10)
Wild-type 29 (44.61) 36 (55.38) 65 (61.90)
*Chi-square test or Student’s t-test was used to investigate difference between groups.
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Overall survival analysis in primary melanoma not treated
with immunotherapy
In the population of patients who had never received
immunotherapy, PD-L1 expression and CD8+TIL status anal-
ysed alone were not significant prognostic factors (P = 0.11 and
P = 0.61, respectively); data not shown). Conversely, the PD-L1/
CD8+TIL status was significantly associated with favourable OS
(P = 0.015; Fig. 5a).
The PD-L1/CD8+TILs+ subgroup compared to the other
three groups was significantly correlated with better OS
(P = 0.009; Fig. 5b), with a percentage of patients alive at
60 months of 83% (15/18) vs. 47% for the other three groups
combined (17/36). These results were confirmed in a multivari-
ate analysis that showed that PD-L1/TILs+ status was a good
independent prognostic factor (HR, 0.05; 95% CI, 0.007–0.36;
P = 0.002).
In contrast, the PD-L1+/CD8+TILs+ status, compared to
the other three groups, was a poor prognostic factor
(P = 0.014; Fig. 5c). The percentage of patients alive at
60 months was 37% (6/16) compared to 68% for the three
combined groups (26/38). The PD-L1+/CD8+TILs+ status was
confirmed as a significant and independent prognostic factor
associated with poor OS by multivariate analysis (HR, 6.7;
95% CI, 1.63–27.93; P = 0.007).
Overall survival analysis in primary melanoma treated with
immunotherapy
In the population of patients treated by immunotherapy, the
PD-L1 expression and the CD8+TIL status analysed alone were
not significant prognostic factors (P = 0.50 and P = 0.30,
respectively; data not shown).
There was no significant difference in OS when analysing the
PD-L1/CD8+TIL groups individually (P = 0.63). Moreover, the
Figure 1 Various patterns of PD-L1 expression in melanocytic
tumour cells. (a) PD-L1 expressed in 20% of tumour cells at the
periphery of tumour areas (original magnification, 9100). (b)
Heterogeneous PD-L1 expression in 50% of tumour cells (original
magnification, 9100). (c) Strong membranous expression (original
magnification, 9400). (d) Low-to-moderate membranous expres-
sion (original magnification, 9400).
Figure 2 Distribution patterns of tumour-infiltrating lymphocytes
(TILs). (a) HES slide (original magnification, 9100). (b) HES slide
(original magnification, 9200). (c) Periphery excluded infiltrates of
CD8+TILs (original magnification, 9100). (d) Periphery and
intratumoral infiltrates of CD8+TILs (original magnification, 9100).
(e) Immune-desert with the absence of CD8+TILs (original magnifi-
cation, 9100). (f) Peritumoral CD8+TIL infiltrates (original magnifica-
tion, 9100).
Table 2 PD-L1 expression and distribution of the CD8+TILs and







Negative 70 (67%) 64 (61%)
Positive 35 (33%) 41 (39%)
CD8+TILs
Negative 41 (39%) 56 (53%)
Positive 64 (61%) 49 (47%)
PD-L1/CD8+TIL subgroups
PD-L1/TILs 34 (32%) 47 (45%)
PD-L1+/TILs 7 (7%) 9 (9%)
PD-L1/TILs+ 36 (34%) 17 (16%)
PD-L1+/TILs+ 28 (27%) 32 (30%)
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PD-L1/CD8+TIL status compared to the other three groups was
not a significant prognostic factor for OS (P = 0.86; data not
shown). As opposed to that, the PD-L1+/CD8+TIL subgroup was
correlated to better OS with an increased percentage of patients
alive at 60 months compared to the other three groups (66%, 8/
12 of patients alive vs. 53%, 21/39; P = 0.034; Fig. 5d).
In the multivariate analysis, including age (HR, 2.277;
















































Figure 4 Kaplan–Meier overall survival curves according to PD-L1/CD8+TIL status in the 105 primary melanomas. (a) Analysis of the four
groups PD-L1/CD8+TILs. (b) Analysis of the PD-L1/CD8+TIL group alone compared to the other three groups. The P-values were calcu-
lated using the log-rank test.
Figure 3 Patterns observed in the PD-L1+/CD8+TILs+ and PD-L1/CD8+TILs+ subgroups. Melanoma with inflammatory infiltrate (a,
HES), demonstrating the presence of CD8+TILs (b), associated with the expression of PD-L1 in tumour cells (c). Original magnification,
9100. Melanoma with inflammatory infiltrate (d, HES), demonstrating the presence of CD8+TILs (e), but no expression of PD-L1 in tumour
cells (f). Original magnification, 9100.
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CI, 0.689–7.531; P = 0.501), stage (HR, 3.695; 95% CI,
1.213–11.257; P = 0.018), ulceration (HR, 2.983; 95% CI,
1.298–6.855; P = 0.008) and baseline LDH levels (HR, 0.815;
95% CI, 0.294–2.259; P = 0.687), the stage and PD-L1+/
TILs+ status were significant and independent prognostic
factors associated with OS compared to the other groups
(PD-L1+/TILs+ status; HR, 0.138; 95% CI, 0.024–0.779;
P = 0.022).
Discussion
Treatment with ICIs in patients with metastatic melanoma
demonstrates impressive response rates. However, although the
benefit is restricted to approximately 40% of patients treated
with anti-PD-1 therapy, there are no approved stratification
strategies for immunotherapy in melanoma.25 Thus, there is an































































































Figure 5 Kaplan–Meier overall survival curves according to PD-L1/CD8+TIL status in the primary melanomas non-treated by
immunotherapy (n = 54) or treated by immunotherapy (n = 51). (a) The four groups PD-L1/CD8+TILs in patients non-treated by
immunotherapy. (b) PD-L1/CD8+TILs+ group alone compared to the other three groups, in patients non-treated by immunotherapy. (c)
PD-L1+/CD8+TILs+ group alone compared to the other 3 groups, in patients non-treated by immunotherapy. (d) PD-L1+/CD8+TILs+
group alone compared to the other three groups, in patients treated by immunotherapy. The P-values were calculated using the log-rank
test.
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Melanoma is one of the tumours with the highest somatic
mutation rates among solid tumours, which is thought to be
related to their high immunogenicity (i.e. their ability to induce
an adaptive immune response specifically directed against
tumour antigens).27 In melanoma, the PD-L1 expression in
tumour cells is in most cases adaptive, being rarely related to
constitutive the activation of mitogen-activated protein kinase
pathways.7,28
In agreement with previous studies, we found that the adap-
tive PD-L1 response is constituted by focal expression in tumour
cells, often at the periphery of the tumour, at the tumour inva-
sion front, and close to an inflammatory CD8+TIL.15
The PD-L1 status is notoriously difficult to estimate due to
the variability of methods used across studies but also related to
the intrinsic intra- and inter-tumour heterogeneity.
The IHC tests used in the majority of clinical trials employed
two different clones (e.g. 28-8 and 22C3), and the positivity
thresholds vary from 1% to 5% of tumour cells. Moreover, in
some studies the PD-L1positive immune cells were also taken
into account in evaluating the levels of expression and calculat-
ing the positivity threshold.25 In clinical trials, the most widely
used positivity threshold is ≥5% of tumour cells when using the
pharmDx 28-8 kit.4,5,20,29
Second, there are significant variations in PD-L1 expression
within the same tumour and between samples from different
tumour sites in the same patient.30,31 Given the intratumour
heterogeneity and in order to analyse the largest tumour area, we
evaluated the expression of PD-L1 on whole tissue sections, which
can better reflect the distribution and type of cells expressing PD-
L1 and also allows assessing the relationship between PD-L1
expression on tumour cells and on immune cells.
As a consequence of the adaptive immune resistance mecha-
nism and the existence of immunogenic or non-immunogenic
tumours, the infiltration of immune cells into the tumour, par-
ticularly T cells, associated with the expression of PD-L1 could
be an important predictive biomarker for PD-1/PD-L1 check-
point inhibitors.32
In our study, the proportion of primary melanomas express-
ing PD-L1 on tumour cells was 33%, similar to some previous
reports,15 while other studies reported higher rates. One study
observed PD-L1 positivity in 51% of cases, but with a positivity
threshold of 1%,30 whereas another study using a 5% threshold
reported 53% PD-L1positive rate; however, the site of sam-
pling, primary or metastatic, was not specified.7
Most studies that have investigated the predictive value of
PD-L1 expression for the response to anti-PD-1/PD-L1 therapy
in metastatic melanomas have not distinguished the primary or
metastatic site.7,13,19 In our study, the PD-L1 expression was
more frequent in metastases (39% vs. 33%). Our results are sim-
ilar to a study by Taube et al.15 (43% vs. 35%), while conflicting
results have been reported by Madore et al.30 (51% for primary,
57% for regional metastases and 42% for distant metastases).
We did not find any significant association between PD-L1
expression on tumour cells of primary melanoma and OS, as
previously shown.15,33 In melanoma, the prognostic significance
of PD-L1 expression remains controversial, being associated
with either a poor8–10 or a better prognosis.11
In our cohort, PD-L1 expression was not significantly asso-
ciated with the response of PD-1/PD-L1 agents. Whereas the
expression of PD-L1 by tumour cells may be predictive of a
good response to immunotherapy, nevertheless, a significant
clinical benefit can also be observed in most studies in the
negative PD-L1 group, even if response rates remain
lower.6,7,34 Overall, the variability of the methods used, the
absence of a standardized positivity threshold, the spatio-tem-
poral heterogeneity and the presence of an immunotherapy
response in PD-L1negative patients are such that PD-L1 does
not appear to be a good standalone biomarker for response to
immunotherapy in melanoma.
The presence of intratumoral CD8+TILs is frequently
observed in melanomas.15 In our study, 60.9% of primary mela-
nomas had a positive CD8+TIL status with a lower rate in the
metastatic samples, for any site combined (46.6%).
In the whole population, we have not found a significant asso-
ciation between the presence of CD8+TILs in primary melanoma
or metastases and OS, as previously observed in other series.32,35
Most studies have shown that the presence of a high density of
TILs in primary melanomas was significantly associated with
better outcome,36,37 suggesting that a functional lymphocyte
infiltration is necessary for the effectiveness of PD-1/PD-L1
blockage. Moreover, the CD8+TIL status, studied alone in our
series, was not predictive of response, unlike previous
reports.13,34
However, the presence of CD8+TIL infiltrate in the tumour
could be an important clinical biomarker when combined to
PD-L1 expression. Two studies suggested that the expression of
PD-L1 should be interpreted taking into account the tumour
microenvironment. The tumours were categorized into 4 differ-
ent types of tumour microenvironment based on the presence or
absence of TILs and PD-L1 expression, suggesting that this clas-
sification could be more effective to predict the response to
immunotherapy.14,15
In our study, the association between the PD-L1 expression
and the presence of CD8+TILs was found in 26.6% of the pri-
mary melanomas, the majority groups being the CD8+TIL/
PD-L1 and CD8+TIL+/PD-L1 groups. PD-L1 expression
without associated CD8+TILs was rare.
These observations were different on metastatic samples. The
CD8+TIL/PD-L1 group became the majority while the
CD8+TIL+/PD-L1 group was half as high as in primary mela-
nomas. It is interesting to note that approximately the same dis-
tribution of these different groups was found by Taube et al.,15
on both primary and metastatic melanomas. A review of the lit-
erature reports a different distribution showing a predominance
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of CD8+TIL+/PD-L1+ (38%) and CD8+TIL/PD-L1 (41%)
status but without distinction between primary and metastatic
melanomas.14
Certain CD8+TIL/PD-L1 subgroups demonstrated prognostic
and predictive value in the 105 primary melanomas, depending
on the patient group studied, general population, patients trea-
ted or not by immunotherapy.
Thus, the group of patients with PD-L1/CD8+TILs+ status
is a group with a good independent prognosis in the general
population and even more significantly in the group of patients
not treated with immunotherapy. Conversely, in the group of
patients treated with immunotherapy, this profile was not a sig-
nificant prognostic factor for OS. It would appear that patients
with PD-L1/CD8+TILs+ tumours are not good responders to
immunotherapy. Indeed, immunotherapy does not seem to
improve their survival.
Interestingly, our results suggest that for the choice of first-
line treatment of mutated BRAF patients, the PD-L1/
CD8+TILs+ subgroup could benefit from a combination of tar-
geted therapy (anti-BRAF and anti-MEK). On the other hand,
the PD-L1+/CD8+TILs+ subgroup, which is correlated with a
good prognosis when treated with immunotherapy, could bene-
fit from first-line immunotherapy, despite the mutated BRAF
status. There was no significant correlation between PD-L1
expression and BRAF mutation status, as previously showed in
the literature.38
Furthermore, we showed that the PD-L1+/CD8+TILs+ pro-
file was an independent factor of poor prognosis, significantly
observed in the group of patients not treated with
immunotherapy, with only 37% of patients alive at 60 months.
Conversely, in patients treated by immunotherapy, this profile
was an independent factor associated with better outcome,
with 66% of patients still alive at 60 months, as previously
reported in cutaneous melanomas.13,39 In the whole study
population and without distinguishing therapeutic manage-
ment, these results were not significantly discriminated. The
tendency of the PD-L1+/CD8+TILs+ subgroup to have a poor
prognosis appears to be masked in the general population by
patients who have received immunotherapy and whose prog-
nosis has been improved.
With regard to the PD-L1/CD8+TILs profile, we could not
show a prognostic or predictive significance for response to
immunotherapy. However, the percentage of patients alive at
60 months in the general population and in the groups of
patients treated or not with immunotherapy remained stable
around 47%. This suggests that the absence of CD8+TILs associ-
ated with the absence of PD-L1 expression may be a poor prog-
nostic factor, associated with the absence of response to
immunotherapy.
Teng et al.14 suggest that, given the absence of pre-existing
functional T lymphocytes, the PD-L1/CD8+TILs profile
would be associated with poor prognosis and patients would
then likely not respond to anti-PD1 monotherapy, whereas the
combination of anti-CTLA4 and anti-PD1 agents would be
beneficial for these patients. Indeed, anti-CTLA4 would allow
early activation of T cells that would be recruited into the
tumour and induce adaptive expression of PD-L1, which
would then be the target of anti-PD1.14 The immunotherapy
combinatorial strategies were not in the scope of our study;
however, such strategies are of high importance for tumours
that do not express PD-L1, and it would therefore be interest-
ing to study the efficacy based on the four PD-L1/CD8+TIL
patterns.29,40
Finally, the PD-L1+/CD8+TILs status was not found to be a
prognostic nor predictive factor for a response to immunother-
apy in any of our patient groups. However, this status, reflecting
a constitutive expression of PD-L1, is very poorly represented in
our series, as in the various series described in the literature.15
Finally, while the CD28 expression was not significantly associ-
ated with outcome, the Ki67 expression was significantly associ-
ated with poor survival in the PD-L1/CD8+TILs+, suggesting
that the prognostic value may be driven by activated CD8+T cells
in the absence of PD-L1 expression.
There are a number of limitations in our study. This is a sin-
gle-institutional retrospective study with a modest sample size,
even though all available cases at Nice University Hospital were
collected at the time of the study. Although the hypothesis of
this study is well-substantiated in the literature, an independent
validation cohort would be optimal.
Another limitation is related to the heterogeneity of the 51
patients treated with immunotherapy. Although the majority of
patients received anti-PD-1 monotherapy, few patients had two
different lines of immunotherapy (anti-CTLA4 followed by anti-
PD-1) and more rarely other types of associated treatments
(chemotherapy or targeted therapy) during the follow-up.
In summary, our study shows that PD-L1 expression alone is
not a robust prognostic factor in patients with metastatic malig-
nant melanoma, whether this status is assessed on the primary
tumour or on the matched metastasis. In exchange, the addi-
tional assessment of the CD8+TIL infiltrates could better assess
the OS of subgroups of patients and predict the therapeutic
response of patients with metastatic melanoma treated by either
immunotherapy or other treatment regimens. Moreover, this
IHC assay can be easily applied to current conventional routine
testing and may offer valuable clinical information when consid-
ering different treatment options in the absence of established
methods for patient stratification.
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